These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7989480)

  • 1. Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1716-22. PubMed ID: 7989480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen replacement does not potentiate gonadotropin-releasing hormone agonist-induced androgen suppression in treatment of hirsutism.
    Tiitinen A; Simberg N; Stenman UH; Ylikorkala O
    J Clin Endocrinol Metab; 1994 Aug; 79(2):447-51. PubMed ID: 8045961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement.
    Simberg N; Tiitinen A; Silfvast A; Viinikka L; Ylikorkala O
    J Clin Endocrinol Metab; 1996 Feb; 81(2):646-51. PubMed ID: 8636283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.
    Carr BR; Breslau NA; Givens C; Byrd W; Barnett-Hamm C; Marshburn PB
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1169-78. PubMed ID: 7714086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome.
    Chung JP; Yiu AK; Chung TK; Chan SS
    J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):166-71. PubMed ID: 24656700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism.
    Carmina E; Janni A; Lobo RA
    J Clin Endocrinol Metab; 1994 Jan; 78(1):126-30. PubMed ID: 8288696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of low-dose GnRH analogue (Buserelin) in the treatment of hirsutism.
    Bertoli A; Fusco A; Magnani A; Marini MA; Di Daniele N; Gatti S; Lauro R
    Exp Clin Endocrinol Diabetes; 1995; 103(1):15-20. PubMed ID: 7621099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
    Rittmaster RS; Thompson DL
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy.
    Morcos RN; Abdul-Malak ME; Shikora E
    Fertil Steril; 1994 Mar; 61(3):427-31. PubMed ID: 8137961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis].
    Wang YQ; Zhang SF; Chen X; Zhu J; Hua KQ; Hu WG
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):504-8. PubMed ID: 19957549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing hormone agonist leuprolide.
    Rittmaster RS
    J Clin Endocrinol Metab; 1988 Oct; 67(4):651-5. PubMed ID: 3138274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism.
    Bayhan G; Bahçeci M; Demirkol T; Ertem M; Yalinkaya A; Erden AC
    Clin Exp Obstet Gynecol; 2000; 27(3-4):203-6. PubMed ID: 11214952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).
    Andreyko JL; Monroe SE; Jaffe RB
    J Clin Endocrinol Metab; 1986 Oct; 63(4):854-9. PubMed ID: 2943756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE; Anania C; Malinak R
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide.
    Ibáñez L; Potau N; Marcos MV; de Zegher F
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3251-5. PubMed ID: 10999817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.
    Steingold K; De Ziegler D; Cedars M; Meldrum DR; Lu JK; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1987 Oct; 65(4):773-8. PubMed ID: 3116031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.